NIH Pays Stanford $782,082 to Develop Influenza Vaccines That Activate Bacterial Endotoxin TLR4 Pathway
Taxpayers are financing synthetic inflammatory stimulants modelled on toxic bacterial chemistry, raising questions about human safety, informed consent, and oversight amid pandemic orchestration.
An August 12, 2026, National Institutes of Health (NIH) award reveals that the federal government awarded Stanford University $782,082 to investigate experimental influenza vaccine formulations designed to activate TLR4, the same immune receptor stimulated by bacterial endotoxin (LPS).
Endotoxins are toxic bacterial components capable of triggering severe inflammation, septic shock, organ failure, and death.
The payment comes as HHS plans for 660 million “pandemic influenza” vaccine doses, renewing a contract system established before the 2009 influenza pandemic.
HHS is also planning to suspend FOIA and pandemic oversight while continuing vaccine and biodefense contracts.
Which raises questions about the Stanford endotoxin-related funding:
Why is NIH spending taxpayer money to develop injections that deliberately stimulate an endotoxin-responsive inflammatory pathway?
Who authorized this approach, who benefits, and who consented to financing it?
Will endotoxins or endotoxin-like substances be inside vaccines authorities push on the population during the next government-orchestrated pandemic response, as was the case with COVID-19 vaccines?
https://jonfleetwood.substack.com/p/nih-pays-stanford-782082-to-develop?publication
